Takamatsu, Shiro http://orcid.org/0000-0002-1569-6421
Yoshihara, Kosuke http://orcid.org/0000-0002-2254-3378
Baba, Tsukasa
Shimada, Muneaki
Yoshida, Hiroshi
Kajiyama, Hiroaki
Oda, Katsutoshi
Mandai, Masaki
Okamoto, Aikou
Enomoto, Takayuki
Matsumura, Noriomi http://orcid.org/0000-0002-4512-7975
Funding for this research was provided by:
Merck & Co., Inc. | Merck Sharp and Dohme (ESR-19-14550)
Article History
Received: 15 July 2022
Revised: 2 December 2022
Accepted: 13 December 2022
First Online: 2 January 2023
Competing interests
: NM received a research grant from AstraZeneca. NM received lecture fees from AstraZeneca and Takeda Pharmaceutical. NM is also an outside director of Takara Bio. TB received lecture fees from AstraZeneca. KY received lecture fees and a research grant from AstraZeneca. There are no other competing interests related to this paper.
: For the JGOG3025 study, i.e., clinical data analysis, frozen tumour tissue collection, target sequencing, and future analyses of tumour tissue, written informed consent was obtained from all patients with approval from the Institutional Review Board at each JGOG participating site prior to the start of the study [CitationRef removed]. The JGOG3025-TR2 study was then conducted with the approval of the Ethics Committee of JGOG and the Institutional Ethics Committee of Kindai University (approval number; 29-167), with opt-out patient consent. This study was performed in accordance with the Declaration of Helsinki.
: Not applicable.